ERBB2 and pancreatic neoplasm: In a phase I trial conducted by Feng KC et al., HER2-targeting CAR-T cells were administered to patients with advanced unresectable pancreatic cancer following pre-treatment with nab-paclitaxel and cyclophosphamide.